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EDITORIAL COMMENTARYRight here waiting...?Song Wan, MD, FRCSSee related article on pages 3092-8.No surgeon in this world likes bleeding. Yet perioperative
blood loss is impossible to avoid when conducting an ‘‘ultra
major’’ cardiovascular operation, such as coronary artery
bypass grafting (CABG). Every member of a ‘‘heart team’’
treats this common complication very seriously, simply
because it has important prognostic implications for pa-
tients.1 Because even outstanding surgical skill and meticu-
lous perioperative management are insufficient to eliminate
perioperative bleeding, prevention is the only real option.
In this regard, the meta-analysis of Cao and colleagues2
in this issue of the Journal is both timely and of utmost
importance. On the basis of a comprehensive review of
the literature, Cao and colleagues2 identified 5 appropriate
clinical studies of 6385 patients with acute coronary syn-
drome (ACS) who had subsequently undergone CABG.
The data for 2632 patients who received preoperative clopi-
dogrel were compared with the data for patients who did not
receive this medication, and the beneficial effect of dual an-
tiplatelet therapy was once again confirmed. Importantly, a
lower incidence of the combined end point of reoperation,
major bleeding, mortality, and myocardial infarction was
observed in 873 patients who underwent clopidogrel
washout for more than 5 days before CABG. Cao and col-
leagues2 concluded that dual antiplatelet therapy including
clopidogrel is favorable for patients with ACS. If CABG is
indicated, however, whenever feasible, clopidogrel intake
should cease for at least 5 days before the cut-and-sew.
Clearly, this clinical recommendation is relevant to
everyone involved in the care of patients with ACS, such
as surgeons, cardiologists, anesthesiologists, and intensive-
care specialists. Indeed, the guidelines provided in 2011 by
both the European Society of Cardiology3 and the American
Heart Association4 supported the proposal made by Cao and
colleagues2 that clopidogrel be withdrawn for 5 days before
CABG. It appears questionable in 2014, however, whether
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meta-analysis2 was based on a rather more limited data set
than that available today, some additional issues should not
be overlooked. For instance, it is now well known that the
platelet-inhibitory effect of clopidogrel varies significantly
among patients. High levels of platelet reactivity have been
observed in 30% to 40% of clopidogrel-treated patients,
particularly thosewith proton-pump inhibitors.5 The uniform
guidelines for clopidogrel discontinuation before CABG are
thus unlikely to be relevant to ‘‘clopidogrel-nonresponder’’
patients. Moreover, the recommended 5-day duration of clo-
pidogrel washout is also debatable, because in some patients
platelet reactivity may take much less time to return to a
normal level. The results of a recent prospective single-
center study showed that using thromboelastography to mea-
sure platelet function can shorten the recommended 5-day
preoperative waiting period for clopidogrel-treated patients
by an average of 46% (2.7 days) without increasing
CABG-related bleeding.6 Logically, the updated guidelines
released by the Society of Thoracic Surgeons in 2012 gave
a class IIa endorsement to the use of platelet-function tests
to make decisions about the timing of CABG, rather than
the uniform use of an arbitrarily specified preoperative
period of withdrawal of dual antiplatelet therapy involving
P2Y12-receptor inhibitors such as clopidogrel.
7
It is also worth noting that more potent P2Y12-receptor
inhibitors, such as prasugrel and ticagrelor, are now avail-
able. Compared with clopidogrel, these inhibitors produce
less interindividual variation in treatment outcomes and bet-
ter clinical results for patients with ACS. They have there-
fore been recommended as replacements for clopidogrel in
the ACS setting.5 More potent drugs may also increase the
incidence of bleeding, however, with particularly negative
implications for the success of surgery if CABG is urgently
needed. Interestingly, it has recently been proposed that
during preoperative discontinuation of P2Y12-receptor in-
hibitors and the subsequent gradual recovery of platelet
function, a ‘‘therapeutic window’’ balancing the risk of
bleeding and ischemia can be identified by appropriate
platelet-function tests.8 This may help to determine the
safer period for CABG. Such concerns highlight the
increasing importance of validated platelet-function tests.
Despite a growing body of evidence supporting the use of
platelet-function monitoring to tailor therapy to patients
receiving irreversible P2Y12-receptor blocker treatment,
no large-scale randomized trial to date has defined the
best assay and assay-specific bleeding cutoffs. Moreover,
it has long been recognized that a wide variety of factors
are involved in the complex interactions causingdiovascular Surgery c Volume 148, Number 6 3099
Editorial Commentary Wanperioperative coagulopathy.9 Among these factors are expo-
sure to the cardiopulmonary bypass circuit, with resultant
contact activation, hemodilution, hypothermia, anticoagu-
lation with heparin and the subsequent reaction with prot-
amine, and fibrinolysis, whereas platelet activation and
the resulting dysfunction play only partial roles in this com-
plex chain of inflammatory events.9 Point-of-care testing
may therefore be particularly important, because it provides
a comprehensive view of blood coagulation.
We may therefore regard the systematic review conduct-
ed by Cao and colleagues2 as a summary of ‘‘the end of the
beginning,’’ which will certainly inspire further scientific
exploration and more bench-to-bedside investigation. Ulti-
mately, it is up to the surgeon to decide whether it is in the
best interests of the patient to remain ‘‘right here waiting’’
or to take further action.References
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